ArticleScientific reports2025
Association between exacerbation history and airway bacterial community assessed by extended bacterial culture and sequencing approaches in stable COPD.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli that cause airflow obstruction. It is a leading cause of death worldwide. While alterations in airway bacterial community have been linked to exacerbation frequency, the underlying mechanisms remain unclear. We aimed to characterize associations between airway bacterial community structure and exacerbation history in stable COPD patients and to identify candidate microbial markers that could assist in risk assessment for the clinical management of COPD patients. Sixty-two stable COPD patients were enrolled and categorized into two groups based on their exacerbation history: low risk (LR) and high risk (HR) of exacerbation. Sputum samples were collected and analyzed using both bacterial extended culture and 16S rRNA gene sequencing. The combination of these approaches provided complementary insights, enabling a more comprehensive characterization of the bacterial community. To our knowledge, this is the first study to combine these two approaches in this context and to evaluate their relative performance in detecting microbiological markers associated with exacerbation risk. Microbial composition analysis revealed a loss of α-diversity in HR patients based on extended culture data, a finding not corroborated by sequencing. This discrepancy suggests that the observed impoverishment of diversity may primarily affect the viable fraction of the airway microbial community. The HR group also exhibited increased relative abundances of Pseudomonadota and Bacteroidota, alongside a marked decrease in relative abundances of Lactobacillus and Streptococcus. Notably, significant reductions in the proportion of positive samples were observed at the species level for Streptococcus salivarius and Streptococcus mutans. A comparison of the two methods underlined that 16S rRNA gene sequencing identified five additional phyla and 84 genera not detected by culture, notably strict anaerobes. However, extended culture demonstrated robust sensitivity in detecting Enterobacterales and the pathogenic Moraxella and Pseudomonas. This study revealed microbiological features linked to exacerbation history in stable COPD patients, highlighting the need for future functional and longitudinal research to validate these airway bacterial community signatures and develop targeted preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.